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Background: Although transplantation of cryopreserved ovarian tissue is a promising approach to restore fertility in
cancer patients, it is not advisable for women at risk of ovarian involvement due to the threat of reintroducing
malignant cells. The aim of this study was therefore to find an alternative for these patients by development of an
artificial ovary.
Methods: For construction of the artificial ovary matrix, we used a central composite design to investigate nine
combinations of fibrinogen (mg/ml) and thrombin (IU/mL) (F/T): F1/T4, F12.5/T1, F12.5/T20, F25/T0.1, F25/T4,
F25/T500, F50/T1, F50/T20 and F100/T4. From the first qualitative analyses (handling and matrix size), five
combinations (F12.5/T1, F25/T4, F50/T20, F50/T1 and F100/T4) yielded positive results. They were further
evaluated in order to assess fibrin matrix degradation and homogeneous cell encapsulation (density), survival
and proliferation (Ki67), and atresia (TUNEL) before and after 7 days of in vitro culture. To determine the best
compromise between maximizing the dynamic density (Y1) and minimizing the apoptosis rate (Y2), we used
the desirability function approach.
Results: Two combinations (F12.5/T1 and F25/T4) showed greater distribution of cells before in vitro culture,
reproducible degradation of the fibrin network and adequate support for isolated human ovarian stromal cells,
with a high proportion of Ki67-positive cells. SEM analysis revealed a network of fibers with regular pores and
healthy stromal cells after in vitro culture with both F/T combinations.
Conclusion: This study reports two optimal F/T combinations that allow survival and proliferation of isolated
human ovarian cells. Further studies are required to determine if such a scaffold will also be a suitable environment for
isolated ovarian follicles.
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While advances in cancer treatment have increased the
survival of cancer patients, more long-term side effects
can be observed in these patients. Aggressive treatments
(particularly alkylating chemotherapeutic agents and total
body radiation) are known to cause secondary menopause
and infertility. Different options are available to preserve
fertility in these young women, but for prepubertal pa-
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stated.cryopreservation of ovarian tissue is the only feasible op-
tion at present. In recent years, ovarian tissue transplant-
ation has proved effective to restore fertility in adults, with
24 live births published to date [1]. However, transplant-
ation of cryopreserved ovarian tissue cannot be safely per-
formed when there is a risk of reimplanting malignant
cells. Patients suffering from cancer with a high risk of
ovarian involvement, such as leukemia, neuroblastoma or
Burkitt lymphoma, are therefore not advised to undergo
ovarian tissue transplantation [2]. Indeed, a previous study
proved, by PCR analysis and long-term xenografting, ma-
lignant cell contamination of cryopreserved ovarian tissue
from leukemia patients [3]. This risk may also be present
in other types of cancer [2] and for these patients, inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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new options need to be developed.
One alternative that can be proposed is grafting of iso-
lated ovarian follicles [4]. This technique may be consid-
ered safe because ovarian follicles are surrounded by
a basal membrane, excluding them from the stromal
environment, capillaries and nerves [5]. The main chal-
lenge is to develop a scaffold which encapsulates these
isolated follicles, supporting their survival and growth
after transplantation. The structure should maintain the
three-dimensional (3D) architecture of ovarian follicles
and degrade relatively quickly to allow growth of pre-
antral follicles up to the antral stage. In our research
unit, previous studies have demonstrated that isolated
human ovarian follicles encapsulated in plasma clots
can survive after grafting to immunodeficient mice
for one week [4] and develop up to the antral stage
after 6 months’ xenografting [6]. Despite these already
promising results, we believe we could improve follicle
survival and growth and reorganize this artificial ovary
into a functioning organ by adding isolated ovarian
cells [7]. Indeed, isolated ovarian cells, including stro-
mal and endothelial cells, have demonstrated their
primordial role in the formation of a well vascularized
and structured ovary-like stroma after one week of
grafting [8]. However, plasma clots are difficult to han-
dle, leading to follicle loss.
Fibrin plays an integral part in physiologic blood co-
agulation. Fibrinogen is a soluble 340 kDa protein that is
polymerized into fibrin through the action of thrombin,
an active enzyme in the presence of calcium. Factor
XIIIa, activated by thrombin, then crosslinks fibrin by
the formation of covalent lysyl-glutamine bonds [9-11].
Varying concentrations of fibrinogen and thrombin
can influence the morphology and rigidity of the fi-
brin network, and therefore cell proliferation [12,13].
Numerous research domains have been studying the
potential of fibrin gel in tissue engineering. Fibrin can be
employed as a vehicle for cell transplantation and delivery
of growth factors, hormones or bioactive substances [14].
For instance, transplantation of mesenchymal stem cells in
fibrin gel has been studied for cartilage regeneration [15].
Fibrin scaffolds have been developed for future therapeutic
strategies in muscular dystrophy, with transplantation of
myoblasts, or for bone marrow engineering, with grafting
of cord blood-hematopoietic stem cells [16]. Fibrin can be
also combined with other substances to promote growth of
human amniotic mesenchymal stem cells, in order to im-
prove myocardiac function [17].
Based on these successful studies, we decided to de-
velop a fibrin scaffold that would allow survival and
proliferation of isolated human ovarian cells. The aim
of the present study was therefore to determine the
optimal combination of fibrinogen (F) and thrombin (T)concentrations. Through establishment of an experimen-
tal design, we tested different fibrinogen and thrombin
combinations (F/T) and analyzed the morphological
parameters of fibrin clots. We also used an in vitro
culture model with isolated human ovarian stromal
cells to evaluate cellular survival and proliferation in
the different fibrin clots. This project is the first step in
building a 3D biodegradable fibrin scaffold, allowing sur-
vival and development of isolated ovarian follicles and
ovarian cells.
Material and methods
Collection of human ovarian tissue
Use of human ovarian tissue was approved by the Insti-
tutional Review Board of the Université Catholique
de Louvain (Comité d’Ethique Biomédicale Hospitalo-
Facultaire 2012/23MAR/125, N° Enregistrement Belge
B403201213872). Ovarian biopsies were obtained from
four patients between 26 and 51 years of age (mean ± SD:
44.48 ± 11.80) undergoing laparoscopy for benign gyne-
cological disease. All women agreeing to donate tissue
signed the cryopreservation informed consent form. Biop-
sies were immediately transported on ice to the laboratory
in Dulbecco’s modified Eagle’s medium (DMEM) and F12
medium containing L-glutamine and 15 mM HEPES
(Gibco, Invitrogen, Merelbeeke, Belgium).
Ovarian stromal cell isolation procedure
The medullar part of the biopsy was removed with surgical
scissors and ovarian cells were isolated using the protocol
developed by Vanacker et al. [18]. Briefly, the cortex was
cut into 0.5 × 0.5 × 1 mm pieces using a tissue sectioner
(McIlwain Tissue Chopper, Mickle Laboratory, Guildford,
UK) adjusted to 0.5 mm. The minced human ovarian tissue
was then transferred to a conical tube containing 10 ml
Dulbecco’s phosphate-buffered saline (PBS) with calcium
and magnesium (Lonza, Verviers, Belgium) supplemented
with 0.04 mg/ml of Liberase DH (Roche, Vilvoorde,
Belgium). Incubation was performed in a water bath at
37°C for 75 min with agitation (120 RPM). The tissue
was pipetted every 15 min to mechanically disrupt it. En-
zymatic activity was inactivated by adding an equal vol-
ume of Dulbecco’s PBS without calcium and magnesium
supplemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich, Bornem, Belgium). The digested cell solution
was successively filtered through 80 μm and 11 μm nylon
net filters (Millipore, Brussels, Belgium). After centri-
fugation, the pellet was re-suspended in 2 mL culture
medium (DMEM-F12 containing 10% FBS, 100U/mL
penicillin and 100 μg/mL streptomycin), and cells were
counted using Trypan Blue (Sigma-Aldrich) and a Bürker
chamber (VWR, Leuven, Belgium). The pellet containing
ovarian cells was diluted in order to obtain a density of
10,000 cells/cm2 in culture flasks.
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Ovarian stromal cells were plated in T-75 plastic flasks
(Nunc, Rokskilde, Denmark) and left to adhere for
15 min. Supernatant medium containing cellular debris
and non-adherent cells was discarded and replaced with
10 mL fresh culture medium. Culture flasks were incu-
bated in a humidified atmosphere with 5% CO2 in air.
Culture medium was renewed every 2 days until cellular
confluence was achieved. After 22 days of in vitro cul-
ture, Accutase® (Sigma-Aldrich) was used for detachment
and dissociation of anchorage-dependent cells from the
plastic flasks. Cells were counted in a Bürker chamber.
After centrifugation, the pellets were resuspended in
DMEM-F12 + 10% FBS medium in order to obtain a
final concentration of 10,000 ovarian stromal cells/5 μl
of medium.
Formation of fibrin clots
Tissucol is a two-component fibrin sealant provided by
Baxter (Braine-l’Alleud, Belgium). When combined, the
two components, sealer protein and thrombin, physiolo-
gically mimic the final stage of the blood coagulation
cascade. The active ingredient in sealer protein (human)
is fibrinogen. Fibrinogen (100 mg/mL) was reconstituted
in a solution containing 3000KIU/mL of bovine aprotinin,
a fibrinolysis inhibitor, at 37°C. Thrombin (500 IU/mL)
was reconstituted in 40 mmol/mL of calcium chloride
(CaCl2) solution. The reconstituted fibrinogen was diluted
in saline solution (NaCl 0.9%) (9 g/L of sodium chloride)
to various concentrations ranging from 1 to 100 mg/mL,
while thrombin was diluted in 40 mmol/L CaCl2 solution.
The above dilutions yielded five different concentrations of
reconstituted fibrinogen, 1 (F1), 12.5 (F12.5), 25 (F25),
50 (F50) and 100 mg/mL (F100), and five concentrations
of thrombin, 0.1 (T0.1), 1 (T1), 4 (T4), 20 (T20) and
500 IU/mL (T500). The resulting combinations of the two
components are shown in Figure 1.Figure 1 Representation of the different analyzed combinations of fibA droplet of 12.5 μL fibrinogen was placed on a glass
petri dish and 50,000 human ovarian cells in 5 μL of
medium were mixed with the fibrinogen. This droplet,
containing isolated ovarian cells, was mixed with a
12.5 μL volume of thrombin on a plastic petri dish. The
resulting fibrin clot was incubated at 37°C for 45 min.
After incubation, the clot was gently detached and used
for different steps. For each combination, one fibrin clot
was embedded in 2% agarose (UltraPure™ Agarose,
Invitrogen, Merelbeke, Belgium), fixed in 4% formalde-
hyde for 24 hours (control) and embedded in paraffin for
histological and immunohistochemical studies. Another
fibrin clot was fixed in 2.5% glutaraldehyde for future
analysis by scanning electron microscopy. Two further fi-
brin clots were assigned to in vitro culture for one week
in the same culture conditions as described above. After
one week of in vitro culture, the clots were fixed in 4%
formaldehyde and 2.5% glutaraldehyde.
Histological analysis and cell density
Paraffin-embedded fibrin clots were cut into serial sec-
tions of 5 μm. Every fourth section was stained with
hematoxylin-eosin (Merck, Darmstadt, Germany) for
histological analysis. The other sections were kept for
immunohistochemical staining (Superfrost Plus slides,
Menzel-Glaser, Braunschweig, Germany).
To evaluate cell density (number of cells per surface
unit), 2 or 3 representative sections from fresh controls
(day 0) and after in vitro culture (day 7) were examined
at 50× magnification, and digitized by means of a Leica
DFC295 camera and imaging program (Leica Application
Suite, Leica). Using ImageJ, a freely available image-
processing and analysis program developed at the National
Institutes of Health (http://rsb.info.nih.gov/ij/), all cells
found in sections from fresh controls and after in vitro cul-
ture were counted, and analyzed areas of the fibrin clots
were measured.rinogen and thrombin.
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culture, expressed in %, was determined by the following
equation:
Density day7‐Density day 0 100
Density day 7
Ovarian stromal cell proliferation
For each F/T combination in different conditions (before
and after in vitro culture), one representative slide was
immunostained to measure proliferative activity using
Ki67 antibody. Sections were deparaffinized with Histo-
safe (Yvsolab SA, Beerse, Belgium) and rehydrated in 2-
propanol (Merck). Endogenous peroxidase activity was
blocked by incubating them with 0.3% H202 (Merck) for
30 min at room temperature. After demasking in citrate
buffer (pH 6) for 75 min at 98°C, non-specific binding
sites were blocked by incubation with normal goat
serum for 30 min. The sections were then incubated
overnight at 4°C with primary antibody, a mouse mono-
clonal anti-human Ki67 antibody (M7240, 1:100 dilution,
Dako, Glostrup, Denmark). The slides were subsequently
incubated for 60 min at room temperature with goat
anti-mouse secondary antibody (Dako). Diaminoben-
zidine (Dako) was used as a chromogen and hematoxylin
as a counter-stain. Human proliferative endometrium was
used as a positive control for Ki67 labeling. Negative
controls consisted of the dilution solution without any
anti-human Ki67 antibody. The proliferation index was
evaluated as the percentage of Ki67-positive cells for each
combination.
Ovarian stromal cell apoptosis
Apoptosis was analyzed by terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)
to detect DNA fragmentation using the In Situ Cell
Death Detection Kit, TMR Red (Roche). The complete
protocol was previously described in detail by Martinez-
Madrid et al. [19] and Vanacker et al. [20]. The slides
were examined under an inverted fluorescence microscope
(Leica; Van Hopplynus Instruments, Brussels, Belgium).
Red fluorescence was visualized in TUNEL-positive cells
by applying an excitation wavelength in the range of 520-
560 nm, and observing the emitted light at a wavelength
between 570 and 620 nm. Pictures were taken of the sec-
tions and ImageJ was used for morphometric analysis of
TUNEL-positive surface areas in order to quantify apop-
tosis. The apoptosis rate was evaluated as the percentage
of TUNEL-positive cells for each combination.
Fibrin degradation
Degradation of the different fibrin formulations was
assessed both macroscopically and histologically. Afterin vitro culture, all clots were measured and observed
for the presence of a residual fibrin matrix.
Scanning electron microscopy (SEM) analysis
After fixation in a 2.5% glutaraldehyde solution, samples
were dehydrated successively in baths of different etha-
nol concentrations (30%, 50%, 70% and 85% ethanol for
15 min each; 100% ethanol for 30 min). The next step
involved critical point drying to preserve sample morph-
ology. Using a Balzers CPD030 critical point drier (Bal Tec
AG, Fürstentum, Liechtenstein), solvent was progressively
replaced with liquid carbon dioxide (CO2) thanks to ex-
change fluids like ethanol. The liquid CO2 was then
brought to its critical point and converted to the gaseous
phase by increasing pressure and temperature. The dried
samples were mounted on stubs containing carbon adhe-
sives. Sputter coating with gold (15 nm) was applied to
samples with a Balzers Union sputtering device (type
07 120B, Bal Tec AG). The samples were stored at
room temperature until analysis with a Jeol 7500-F
scanning electron microscope at a resolution of 1.0 nm at
15 kV.
Experimental design
In order to determine the optimal fibrin formulation for
isolated preantral follicles and ovarian cells, namely the
optimal combination of thrombin and fibrinogen that
maximizes density dynamics (%) and minimizes the apop-
tosis rate (%), we developed an experimental design. It was
based on a central composite design (CCD), which allows a
second order (quadratic) model to be constructed for re-
sponse variable(s). It comprises minimum of nine runs,
each run corresponding to a combination of the two fac-
tors investigated: four points from the two-level factorial
design, four axial points, and at least one run in the center
of the design. The center points are usually chosen as the
most reliable.
Based on several studies [9,12,13,21], the domain to be
covered by the design was set between 1 and 100 mg/ml
for fibrinogen and between 0.1 and 500 IU/ml for
thrombin. The most promising point was composed
of 25 mg/mL fibrinogen and 4 UI/mL thrombin. This
combination was chosen because it is very similar to
a plasma clot: a low thrombin concentration forming
clots with thick fibrin fibers [22] and a higher deg-
radation rate.
Around this central combination, we defined a squared
area of interest corresponding to the two-level factorial
part of the CCD. The four corresponding runs were named
F12.5/T1, F12.5/T20, F50/T20 and F50/T1 (Figure 1).
The four axial points were set as extreme combina-
tions of thrombin and fibrinogen of our domain. Due to
asymmetry of the domain on both sides of the theoret-
ical best concentration of thrombin, we had to modify
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concentration of thrombin was not symmetrically dis-
tributed around the central point.
Statistical analysis
To determine the best compromise between maximizing
density dynamics (Y1) and minimizing the apoptosis rate
(Y2), we used the desirability function approach [23].
Each response variable Yi (i = 1, 2) was assigned a desirabil-
ity function Di that mapped Yi to [0, 1], with Di(Yi) = 0
(response Di(Yi) = 1) when Yi was at a completely undesir-
able (response completely desirable) value. We chose linear
desirability functions. Simultaneous optimization of Y1 and
Y2 was then reduced to yield maximization of an overall
desirability function D defined using a geometric mean:
D ¼ √ D1 Y1ð Þ þ D2 Y2ð Þ½ 
where Y1 and Y2 were replaced by their corresponding
values Ŷ1 and Ŷ2 obtained from a linear model. The design
thus allowed quadratic terms. We further included a ran-
dom effect to account for correlation between repeated
measurements.
Results
By means of qualitative and quantitative analyses, we
aimed to define the best F/T combination that would de-
grade the fastest and allow proliferation of stromal cells,
which in turn would build an adequate environment for
ovarian follicles.
Qualitative analysis of nine fibrinogen/thrombin
combinations
In a first step, we analyzed nine F/T combinations estab-
lished by the experimental design (Figure 1) and selected
those that met the following criteria for a reproducible
and standard protocol:
 homogeneous fibrin clot formation;
 easy handling of fibrin constructs;
 correct encapsulation of cells.
With F1/T4, fibrin clots were very small in size (less than
1×1 mm) and difficult to manipulate with thin forceps.
Fibrin clots from other combinations ranged between
1×5 mm and 6×5 mm in size and were easier to handle.
We observed that the volume of fibrin clots increased in
correlation with fibrinogen concentrations. With two other
combinations (F25/T500 and F12.5/T20), the polymeri-
zation of fibrin was too rapid and the clots became stuck
inside the micropipette tips during the mixing of the two
components. With F25/T0.1, the fibrin clots were fragmen-
ted after incubation and detachment from the plastic petri
dish. These four F/T combinations did not therefore meetall required criteria. The remaining five combinations
(F12.5/T1, F25/T4, F50/T20, F50/T1 and F100/T4) were
easily and reproducibly securated and manipulated.
Quantitative analysis of five fibrinogen/thrombin
combinations
Cell distribution and fibrin degradation
Based on the qualitative criteria described above, five com-
binations were chosen. They were analyzed with quantita-
tive parameters soon after inclusion of isolated human
ovarian stromal cells and also after one week of in vitro cul-
ture. Histological results on day 0 and day 7 after in vitro
culture are shown in Figures 2 and 3, where the distribution
of cells inside the fibrin clots can be observed. Macroscop-
ically and histologically, the clots were found to be reduced
in volume and size (less than 1×1 mm) after one week of
in vitro culture. In some cases, residual fibrin was encoun-
tered after culture in histological sections. The most repro-
ducible histological results were obtained with F25/T4 and
F12.5/T1 combinations, taking into account the spatial uni-
formity of cell distribution, homogeneity of the fibrin net-
work and residual fibrin after one week of in vitro culture.
Cell density, proliferation and survival after one week
of in vitro culture
To quantitatively compare the 5 combinations, cell density
was analyzed on day 0 and day 7, and the dynamics of cell
density was calculated. These results, together with prolif-
eration and apoptosis indices, are shown in Table 1.
For the dynamics of cell density, we rather curiously
observed a negative result for one F100/T4 fibrin clot:
cell density was better before as opposed to after in vitro
culture. For the other combinations, cell density dynamics
ranged from 94.2% to 98.9% (F25/T4), 78.1% to 98.0%
(F50/T1), 57.5% to 97.8% (F50/T20) and 94.0% to 96.6%
(F12.5/T1).
The proliferation index varied between 1.35 ± 1.24%
(F50/T1) and 5.10 ± 3.40% (F100/T4). No significant dif-
ference was observed between the combinations in
terms of proliferation index.
The apoptosis rate also showed great variation for each
combination, except for F100/T4. For F12.5/T1, for ex-
ample, it ranged from 0.9% to 75.6%. The range of the
apoptosis index varied between 3.77 ± 1.17% (F100/T4)
and 26.99 ± 23.45% (F25/T4).
Statistical analysis, based on the desirability function
approach (Harrington, 1965), yielded the following order:
(1) F12.5/T1, (2) F25/T4 and F100/T4, (3) F50/T1 and
F50/T20.
Scanning electron microscopy analysis of two
fibrinogen/thrombin combinations
Based on the results of quantitative analysis of the fibrin
clots, we chose two F/T combinations for SEM analysis:
Figure 2 Representative histological section of different fibrin formulations after encapsulation of isolated human ovarian stromal
cells from four different patients in a fibrin matrix (day 0).
Figure 3 Representative histological section of different fibrin formulations after encapsulation of isolated human ovarian stromal
cells from four different patients in a fibrin matrix and after 1 week of in vitro culture (day 7).
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Table 1 Results obtained after comparison of 5 combinations of fibrinogen and thrombin with in vitro culture of fibrin
clots encapsulating human isolated ovarian stromal cells from four patients (numbered 1 to 4)





mean ± SDDay 0 Day 7
F25/T4 0.0783 ± 0.0376 2.3038 ± 0.5988 96.46 ± 1.97 4.38 ± 4.81 26.99 ± 23.45
F50/T1 0.0524 ± 0.0113 1.8028 ± 1.1627 92.78 ± 9.79 1.35 ± 1.24 18.20 ± 14.94
F50/T20 0.0566 ± 0.0248 1.3848 ± 0.8639 86.89 ± 19.60 3.23 ± 2.66 18.50 ± 10.35
F12.5/T1 0.0757 ± 0.0148 1.6946 ± 0.2691 95.42 ± 1.28 4.45 ± 2.34 23.19 ± 35.11
F100/T4 0.0397 ± 0.0176 0.8243 ± 0.9104 58.29 ± 49.53 5.10 ± 3.40 3.77 ± 1.17
Three different parameters are illustrated: cell density dynamics, proliferation index and apoptosis rate.
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the surface of the clots, the interaction of isolated cells
with fibrin fibers, and the degradation of the clots after
in vitro culture. As shown in Figure 4, fibrin clots from
both F/T combinations showed a network of thick fibers
with regular pores. In both cases, the majority of isolated
stromal cells appeared to be healthy in the fibrin net-
work, evidencing some fingering of the membrane. After
in vitro culture, fibrin was partially or totally degraded
in both F/T combinations, and cells were found to have
proliferated up to a point where they were in close con-
tact with each other (Figure 4D).
Discussion
The aim of this study was to define the optimal F/T
combination for the survival and proliferation of iso-
lated human ovarian stromal cells. From the experimentalFigure 4 Illustrations of fibrin clots by scanning electron microscopy
(day 0) (A, B, C) and after 1 week of in vitro culture (day 7) (D). Two c
and F25/T4 (B, D).design evaluating nine combinations, five met the criteria
for a standardized protocol appropriate for future clinical
applications. Of these five combinations, two (F12.5/T1
and F25/T4) showed reproducible degradation of the
fibrin network and, based on survival and proliferation
analyses, good support for stromal cells, with positive evo-
lution of stromal cell density. Moreover, on SEM, the cells
appeared to have successfully colonized the fibrin matrix,
which was almost or entirely degraded after seven days of
in vitro culture.
Qualitative analysis of nine fibrinogen/thrombin
combinations
The morphology of the fibrin network depends on the
conditions of polymerization and concentrations of fi-
brinogen and thrombin. In our study, we observed that
the fibrinogen concentration influenced the size of the(SEM) after encapsulation of isolated human ovarian stromal cells
ombinations of fibrinogen and thrombin are analyzed: F12.5/T1 (A, C)
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obtained a tiny fibrin clot, but with F100/T4, a very large
matrix. F1/T4 clots were so small that they became
extremely difficult to manipulate. Probably due to the
small pores produced by large amounts of thrombin [24]
and the small final volume size, many cells could not be
encapsulated in clots, explaining the high cell population
observed in the Petri dish after clot polymerization.
It is also important to mention that the thrombin/
fibrinogen ratio is of primary importance because it can
influence polymerization. When the ratio is higher than
1, polymerization starts very quickly. For a reprodu-
cible protocol in our conditions, the two combinations
(F12.5/T20 and F25/T100) with a ratio T/F >1 were too
difficult to manipulate. On the other hand, a very low ratio
is not desirable as reduced concentrations of thrombin can
lower the final level of fibrin [25] and delay fibrin forma-
tion [26]. Indeed, we observed that F25/T0.1 fibrin clots
were fragmented, possibly because the incubation time was
not sufficient for clot formation or due to its flaccidity.
Moreover, as a result of this fragmentation, a high number
of isolated cells were lost outside the clot. Such loss could
also occur with the precious population of isolated pre-
antral follicles.
Quantitative analysis of five fibrinogen/thrombin
combinations
As previously mentioned, quantitative analysis of the
remaining five F/T combinations was performed in order
to choose the best F/T combination for the artificial ovary
by evaluating degradation and the influence of fibrin for-
mulations on cell distribution before in vitro culture, as
well as cell behavior after in vitro culture. In all F/T combi-
nations, cells could be found throughout the matrix on day
0. Only with the F100/T4 combination did cell density
appear lower than with the other fibrin formulations. This
may have been due to clot size, which was increased, with
the same number of cells distributed over a larger area.
After seven days of in vitro culture, we observed deg-
radation and shrinkage of all clots. Some of them com-
pletely disappeared and only cells could be seen, while in
others, a small amount of fibrin was still present around
the cells. This was due to fibrinolysis induced by the
production of plasminogen activators by stromal cells
[27,28] and the absence of aprotinin in the culture
medium that could have inhibited this process [9].
Cell density dynamics showed positive evolution of the
cell population in our fibrin matrices. Although no stat-
istical difference was found between fibrin formulations,
there was a striking numerical difference in the F100/T4
combination, where the density dynamics was lower than
in other combinations. This could have been caused by the
higher fibrinogen concentration and dispersion of the cells
on day 0.The proliferation index was also similar between the
various fibrin formulations. Several studies report that
the combination of different fibrinogen and thrombin
concentrations appears to have an impact on cell prolif-
eration [12,29-31]. For human mesenchymal stem cells
studied for bone tissue regeneration, Bensaid et al. [29]
observed adhesion, spread and proliferation of cells for
fibrin scaffolds with a fibrinogen concentration not higher
than 18 mg/ml. Cox et al. [30] showed that fibroblasts
proliferated well within 3-D fibrin clots containing low
fibrinogen (5-17 mg/mL) and thrombin (1-167 U/mL)
concentrations. According to Duong et al. [9], fibroblasts
prefer to grow and typically exhibit a spread morphology
in lower formulations of fibrinogen and thrombin that
yield lower kPa values for stiffness modulus. All these
observations appear to validate our choice of fibrin formu-
lations, with lower fibrinogen concentrations (F12.5/T1
and F25/T4).
Interestingly, in the F12.5/T1 and F25/T4 combinations,
a high apoptosis rate was also observed. We speculate that
when a critical point is attained, cell death increases be-
cause of the confined space of the fibrin matrix. At this
moment, cells could continue multiplying, but to the detri-
ment of other cells.
Scanning electron microscopy analysis of two
fibrinogen/thrombin combinations
Since F12.5/T1 and F25/T4 combinations offered the
most reproducible results, they were analyzed by SEM.
On day 0, both fibrin formulations showed thick fibers
and regular pores, which can be explained by the mech-
anism involved in fibrin clot formation. Fiber diameter
is determined by a balance between the rate of lateral
aggregation of monomers and the rate of fibrinopeptide
cleavage [32]. The thrombin concentration present during
clot formation is directly related to the rate of fibrinopep-
tide cleavage [32]. Therefore, at low thrombin concen-
trations, the rate of fibrinopeptide cleavage is reduced,
allowing larger lateral aggregation of protofibrils and pro-
duction of thicker fibers.
After in vitro culture, SEM images showed healthy
cells in close contact with each other due to their prolif-
eration and degradation of the fibrin matrix. Chiu et al.
[11] demonstrated that fibrinogen and thrombin concen-
trations have an inverse relationship with the overall
porosity, pore size and, hence, fluid permeability of fi-
brin matrices. Lower concentrations of fibrinogen found
in both these F/T combinations possibly allowed greater
diffusion of nutrients, growth factors and waste removal,
which positively affected cell proliferation.
Conclusions
In conclusion, this study indicates that fibrin formula-
tions with low fibrinogen and thrombin concentrations
Luyckx et al. Journal of Ovarian Research 2013, 6:83 Page 9 of 10
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degradable and biocompatible 3D matrix for isolated
ovarian stromal cells, allowing their survival and prolif-
eration. Our experimental design yielded two combina-
tions that showed encouraging results. The next step
will involve evaluation of the survival and development
of isolated preantral follicles encapsulated in these fibrin
formulations in order to assess if they can be used as a
matrix to construct an artificial ovary.
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